[A18-53] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 03.12.2018
Commission awarded on 27.08.2018 by the Federal Joint Committee (G-BA).
Adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.